Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has completed the rolling submission of a new drug application (“NDA”) seeking approval for its RNAi candidate, lumasiran, as a treatment for primary hyperoxaluria type 1 (PH1). The ultra-rare disease causes a progressive decline in kidney function and can lead to end-stage renal disease. The company had initiated the rolling submission of the NDA in January
The company also submitted a marketing authorization application (MAA) to the European Medicines Agency, seeking approval for lumasiran in patients with PH1. The EMA has accepted the MAA for accelerated assessment, which suggests that a decision is expected in the next 150 days.
Regulatory applications for lumasiran included positive data from the pivotal ILLUMINATE-A study. Data from the study showed that PH1 patients treated with the candidate met the primary efficacy endpoint of percent change from baseline, relative to placebo. The study also achieved statistically significant results for all six tested secondary endpoints including the proportion of patients achieving a near-normalization or normalization of urinary oxalate.
The company is also evaluating lumasiran in two phase III studies — ILLUMINATE-B and ILLUMINATE-C — in PH1 patients less than six years of age with preserved renal function and advanced PH1 in patients of all ages with advanced renal disease, respectively.
Shares of Alnylam have declined 4.9% year to date compared with the industry’s decrease of 7.5%.
Meanwhile, the company is also evaluating several other candidates. A few significant ones include vutrisiran, inclisiran and fitusiran. The HELIOS-A phase III study is evaluating vutrisiran for the treatment of hATTR amyloidosis with polyneuropathy. Another phase III study, HELIOS-B, is evaluating the candidate hereditary and wild-type ATTR amyloidosis with cardiomyopathy. The company is developing fitusiran in partnership with Sanofi (SNY - Free Report) in the ATLAS phase III program for the treatment of hemophilia A or B with and without inhibitors. The company and partner Novartis’ (NVS - Free Report) inclisiran is under review in the United States and Europe for treating heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.
Alnylam has a collaboration with Regeneron Pharmaceuticals (REGN - Free Report) to discover, develop and commercialize new RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the liver, eye and central nervous system.
Alnylam is a Zacks Rank #3 (Hold) stock currently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>